The newer agents seem to have more potent estrogenic effects on bone than are seen with raloxifene and, at the same time, may not be associated with increased endometrial thickness or other uterine effects, a concern that developed with other SERMs
that were being investigated for postmenopausal osteoporosis.
Taylor, professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale, and his colleagues treated breast and endometrial cell lines with either estrogen or estrogen plus one of the SERMs
Pharmaceutical companies are striving to produce the SERM
with the ideal profile of estrogen agonist and antagonist properties for the treatment and prevention of breast cancer, osteoporosis, and cardiovascular disease.
they do not block estrogens at the receptor site as SERMs
FIGURE 6 GLOBAL SERM
MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)
The randomized trials were primarily performed by oncologists, but the application of SERM
prevention falls largely on the primary care community, which cares for patients at risk for breast cancer.
that are currently approved and marketed in the United States have not been shown to have beneficial effects on vaginal tissue and none are approved for use in treating vaginal atrophy symptoms.
Pfizer submitted a new drug application to the Food and Drug Administration in 2007, and in 2008 an advisory panel voted 9-3 that the benefits of the SERM
outweighed this risk in postmenopausal women with osteoporosis.
Selective estrogen receptor modulators (SERMs
) act as estrogen receptor (ER) agonists or antagonist depending on the targeted tissue and the specific configuration of the used SERM
As expected, the SERM
had no effect on the rate of estrogen receptor-negative breast cancers.
A recent article discussed the unexpected adverse events reported in clinical trials of the selective estrogen-receptor modulator levormeloxifene ("Adverse Gynecologic Events Halt Research on Promising SERM
Testing and diligence in the reception of the work entrusted by the SERM
under the arrangements of ZAC in the territory of the city of Montpellier and before delivery of work to the licensing authority.